Stock Watch: AstraZeneca’s Third-Quarter Crescendo
Big Pharma Earnings Season Ends With A Knock-Out Report
Executive Summary
In a third-quarter earnings report that was difficult to fault AstraZeneca left big pharma earnings season on a high note. But raised full-year guidance depends on Evusheld sales and maybe China.
You may also be interested in...
AstraZeneca Confident About Evusheld's Future Growth
Now approved for the treatment as well as the prevention of COVID-19 in the EU and Japan, the UK major’s antibody combo passed the $500m sales barrier in the third quarter and CEO Pascal Soriot is confident that growth will continue.
Stockwatch: Will Coronavirus Drug Developments Rescue The Sector’s Pricing Reputation?
Can the development of coronavirus vaccines and therapeutics reverse the demonization of the pharmaceutical sector brought about by drug price increases?
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.